{"id":"W4214757615","doi":"10.1093/noajnl/vdac025","title":"Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Bristol-Myers Squibb Canada","keywords":"Nivolumab; Temozolomide; Medicine; Tolerability; Internal medicine; Oncology; Clinical endpoint; Adverse effect; Radiation therapy; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002010147,0.0008604557,0.001553961,0.000301992,0.0003222153,0.001004891,0.0009655553,0.0006591433,0.002406386],"category_scores_gemma":[0.001090694,0.0003327476,0.001715064,0.0003852127,0.0005173225,0.000570525,0.0004371983,0.001951162,0.0004456893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001219762,"about_ca_system_score_gemma":0.001773408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001914334,"about_ca_topic_score_gemma":0.005774092,"domain_scores_codex":[0.9996002,0.0002054439,0.00002294574,0.00006740096,0.00004172253,0.00006219195],"domain_scores_gemma":[0.9991775,0.0001097313,0.0001706284,0.00009576746,0.00007617319,0.0003700373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6928032,0.05485998,0.01729474,0.001836548,0.004645606,0.0002227558,0.0004191774,0.003709126,0.06362624,0.0003341298,0.008005156,0.1522433],"study_design_scores_gemma":[0.3611757,0.5561549,0.05813901,0.000185739,0.003076967,0.0004736512,0.0001472299,0.002260972,0.01145868,0.0003382758,0.006501048,0.00008788396],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921156,0.003793481,0.0003577426,0.0001668045,0.0000615281,0.0009257331,0.001583805,0.00006717766,0.0009281562],"genre_scores_gemma":[0.987587,0.003044463,0.001419811,0.0006846972,0.0001105522,0.001374106,0.00465734,0.00004320046,0.00107889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002406386,"threshold_uncertainty_score":0.01063085,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01851337345826857,"score_gpt":0.3102485159173264,"score_spread":0.2917351424590579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}